Onkologie. 2024:18(1):25-31 | DOI: 10.36290/xon.2024.006

Systemic treatment of ovarian cancer

Mária Hanišová¹, Munachiso Ndukwe²

¹ Klinika onkologie a radioterapie, Fakultní nemocnice Hradec Králové

² Porodnická a gynekologická klinika, Fakultní nemocnice Hradec Králové

The most common subtype of ovarian cancer is high grade epithelial serous carcinoma. For several decades, the standard of care has been optimal cytoreductive surgery in combination with platinum-based chemotherapy. Due to the fact that roughly 70% of patients relapse in the first 3 years after induction chemotherapy, strategies are being sought to extend the time until further progression of the disease. Maintenance therapy with targeted drugs (PARP inhibitors and antiangiogenesis inhibitors) is an effective option that makes it possible to extend the time until the disease progresses, it also improves the overall survival and helps to delay the toxicity induced by chemotherapy. The treatment of recurrent ovarian cancer is a therapeutic challenge and new therapeutic approaches (immunotherapy, antibody drug conjugates, FRa inhibitors and others) are being sought to improve the poor prognosis of these patients.

Keywords: ovarian cancer, PARP inhibitors, antiangiogenesis inhibitors.

Accepted: February 22, 2024; Published: February 28, 2024  Show citation